CYGS- COULD BE THE START OF BIG THINGS AHEAD..
(COMTEX) B: M. D. Anderson Cancer Center Collaborates With CYGS to Co
B: M. D. Anderson Cancer Center Collaborates With CYGS to Conduct Clinical
Research of Sense and Anti-Sense Molecules for Psoriasis and Melanoma
HOUSTON, Sep 14, 1999 (BUSINESS WIRE) -- Cryogenic Solutions Inc. (OTC
BB:CYGS) announced today that Madeleine Duvic, M. D. will conduct
clinical research using the company's patented single stranded DNA
intracellular expression vector to deliver sense and anti-sense
molecules into the nucleus of cells for potential treatment of melanoma
and psoriasis.
Dr. Duvic is Chief of the Section of Dermatology and Professor of
Dermatology & Internal Medicine at The University of Texas M. D.
Anderson Cancer Center. She is co-director of the Melanoma Skin Center,
and Translational Research Program in Cutaneous T-cell Lymphoma and
Skin Cancer.
M. D. Anderson Cancer Center is one of the world's most respected
centers devoted exclusively to cancer patient care, research, education
and prevention. M. D. Anderson is one of only thirty-six cancer centers
in the nation designated by the National Cancer Institute as a
Comprehensive Cancer Center. For 10 years, U.S. News and World Report's
"Best Hospitals" issue has ranked M. D. Anderson as one of the two best
cancer centers in the nation.
CYGS is a biomedical research and development company dedicated to
developing enabling technology for the implementation of therapeutic
antisense oligodeoxyribonucleotides (ODN's) into cells to down regulate
the expression of harmful proteins causing a wide variety of diseases
and conditions. The company's proprietary ssDNA expression vector is
currently being used in studies at several leading universities as a
means of overcoming the "delivery barrier" that has impeded the
development of anti-sense therapeutics.
In addition to the research beginning at M. D. Anderson, studies are
underway at seven leading University Medical Schools and three
commercial biotech companies as well as the Southwest Foundation for
Biomedical Research.
The SFBR study will include the required animal testing of the
company's ssDNA expression vector that is prerequisite to any human
trials. The tests will be conducted by Dr. Jason Kimata and supervised
by Dr. Jean Patterson, Chairman of the Department of Virology and
Immunology.
The Simian Immuno Virus (SIV) animal studies are intended to
demonstrate the ability of the CYGS vector to synthesize
pharmacologically significant titers of sequence specific, antisense
competent ODN's in an animal model. "This series, including tissue,
murine and primate studies will demonstrate that we can effectively
overcome the ODN delivery barrier in vivo and with controllable
expression of ssDNA," said CEO, Dr. Malcolm Skolnick.
The role of genes is to control the intracellular production of certain
proteins that effect the condition of the organism. If the genomic
function is improper or impaired, the mutated gene can cause the
production of proteins of a type or in quantities that are harmful.
Numerous congenital defects resulting from faulty genes can originate
at the moment of conception or from mutations later induced by toxins,
viruses, bacteria, radiation, or other environmental influences.
Throughout our lives we are subject to these and other assaults on the
correct working of our genomic plan and activities that interfere with
our health and well being. |
